Peripheral deposition of α1‐protease inhibitor using commercial inhalation devices

Authors:
  • HBH. Beckmann
    H. Beckmann
  • MEM. Maas Enriquez
    M. Maas Enriquez
  • TMT. Meyer
    T. Meyer
  • BMB. Müllinger
    B. Müllinger
  • KSK. Sommerer
    K. Sommerer
  • NWN. Weber
    N. Weber
  • TWT. Weuthen
    T. Weuthen
  • GSG. Scheuch
    G. Scheuch

Abstract
Patients with hereditary α1‐proteinase inhibitor (α1‐PI) deficiency are at risk of developing lung emphysema. To prevent the development of this disease, α1‐PI replacement therapyviainhalation may be a more convenient and effective therapy than the intravenous administration of the drug.In order to optimise this treatment approach, lung deposition of inhaled radiolabelled α1‐PI (Prolastin®) was studied using four different commercial inhalation devices (PARI‐LC Star®, HaloLite®, and AKITA® system in combination with LC Star® and Sidestream®) in six patients with α1‐PI deficiency and mild-to-severe chronic obstructive pulmonary disease.The time required to deposit 50 mg of the Prolastin® (5% solution) in the lung periphery was used as a measure for the efficiency of delivery. The time was calculated from measurements of total and peripheral lung deposition of the radiolabelled α1‐PI. This time was shortest for the AKITA® system (18–24 min) and significantly higher for the PARI‐LC Star® (44 min) and the HaloLite® (100 min).The higher efficiency of drug delivery using the AKITA® system is due to the fact that this device controls breathing patterns, which are optimised for each patient individually.

This publication has 14 references indexed in Scilit: